Group 1 - The Hong Kong Innovative Drug ETF (159567) closed down 0.26% with a trading volume of 221 million yuan on December 26 [1] - The fund was established on January 3, 2024, with an annual management fee of 0.50% and a custody fee of 0.10% [1] - As of December 25, 2024, the fund's latest share count was 10.467 billion shares, with a total size of 8.204 billion yuan, reflecting a year-to-date increase of 2547.36% in shares and 2071.41% in size [1] Group 2 - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 56.94% during the management period [2] - The top holdings of the fund include companies such as BeiGene, CanSino Biologics, Innovent Biologics, and others, with significant weightings in the portfolio [2] - The largest holding is BeiGene, accounting for 10.62% of the portfolio, followed by CanSino Biologics at 10.55% and Innovent Biologics at 10.21% [2]

Core Insights - The GLP-1 market is transitioning from a "blue ocean" to a "competitive battlefield," with local Chinese companies poised to become significant players within three years, leveraging pipeline integration and differentiated innovation [3][14]. Group 1: Company Developments - XinNuoWei, a subsidiary of Shijiazhuang Pharmaceutical Group, plans to establish a joint venture with a total investment of 45 million RMB, focusing on innovative metabolic drugs targeting GLP-1, particularly for obesity and type 2 diabetes [1]. - Shijiazhuang Pharmaceutical Group's revenue for the first three quarters of 2025 was 19.891 billion RMB, a 12.32% year-on-year decline, indicating ongoing financial pressure [9]. - The appointment of Cai Lei as CEO of Shijiazhuang Pharmaceutical Group is expected to enhance the company's international strategy [10]. Group 2: Market Dynamics - The global GLP-1 market reached $35.2 billion in the first half of 2025, with projections to exceed $70 billion for the entire year, reflecting a growth rate of over 40% [4]. - Novo Nordisk's revenue from diabetes and obesity care reached 215.66 billion DKK (approximately $33.24 billion) in the first three quarters of 2025, with GLP-1 drugs contributing 174.58 billion DKK (approximately $26.90 billion), marking a 15% increase year-on-year [4]. - Eli Lilly reported third-quarter revenue of $17.6 billion, a 54% increase year-on-year, with its diabetes drug Mounjaro generating $6.515 billion in sales during the same period [5]. Group 3: Competitive Landscape - The approval of oral semaglutide (Wegovy) by the FDA marks a significant advancement in weight management, being the first oral GLP-1 drug approved for this purpose [2]. - The competition in the GLP-1 market is intensifying, with local companies like HengRui and LaiKai actively developing differentiated products, including dual-target GLP-1/GIP drugs and oral small molecules [8][11]. - The market is witnessing a shift towards oral formulations and multi-target drugs, which are expected to enhance patient compliance and expand market capacity [6][12]. Group 4: Future Trends - The future of the GLP-1 market will focus on multi-target innovations, extended indications, and the development of oral formulations, which are anticipated to be key competitive factors [12][13]. - The entry of local Chinese companies into the GLP-1 market is expected to increase competition significantly, with many companies preparing to launch their products by 2026 [14].

香港联交所最新资料显示，12月23日，主席兼执行董事蔡东晨增持石药集团(01093)670.6万股，每股作 价8.85港元，总金额约为5934.81万港元。增持后最新持股数目约为29.17亿股，最新持股比例为 25.31%。 ...

智通财经APP获悉，香港联交所最新资料显示，12月23日，主席兼执行董事蔡东晨增持石药集团 (01093)670.6万股，每股作价8.85港元，总金额约为5934.81万港元。增持后最新持股数目约为29.17亿 股，最新持股比例为25.31%。 ...

Core Insights - The top three companies by stockholding ratio in the Hong Kong Stock Connect are China Telecom (71.99%), Gree Power Environmental (70.09%), and Da Zhong Public Utilities (68.82%) [1] - Tencent Holdings, Xiaomi Group-W, and Alibaba-W have seen the largest increases in stockholding amounts over the last five trading days, with increases of +1.201 billion, +1.001 billion, and +892 million respectively [1] - The companies with the largest decreases in stockholding amounts over the last five trading days include China Mobile (-2.320 billion), Yingfu Fund (-1.467 billion), and China Petroleum & Chemical Corporation (-364 million) [2] Stockholding Ratio Rankings - China Telecom (00728) holds 9.990 billion shares, representing 71.99% [1] - Gree Power Environmental (01330) holds 0.283 billion shares, representing 70.09% [1] - Da Zhong Public Utilities (01635) holds 0.367 billion shares, representing 68.82% [1] - Other notable companies in the top rankings include Kai Sheng New Energy (67.96%) and Tianjin Chuangye Environmental Protection (67.10%) [1] Recent Increases in Stockholding - Tencent Holdings (00700) saw an increase of +1.201 billion, with a change of +1.9922 million shares [1] - Xiaomi Group-W (01810) increased by +1.001 billion, with a change of +25.5161 million shares [1] - Alibaba-W (09988) increased by +892 million, with a change of +6.1091 million shares [1] - Other companies with significant increases include Hong Kong Exchanges (6.48 billion) and Changfei Optical Fiber (6.09 billion) [1] Recent Decreases in Stockholding - China Mobile (00941) experienced a decrease of -2.320 billion, with a change of -28.0154 million shares [2] - Yingfu Fund (02800) decreased by -1.467 billion, with a change of -56.4370 million shares [2] - China Petroleum & Chemical Corporation (00857) decreased by -364 million, with a change of -44.7216 million shares [2] - Other companies with notable decreases include China Pacific Insurance (-350 million) and Innovent Biologics (-293 million) [2]

Core Insights - Tencent Holdings (00700), Alibaba-W (09988), and Hong Kong Exchanges (00388) led the market in net inflows, with amounts of 1.115 billion, 1.055 billion, and 309 million respectively [1] - China Mobile (00941), Luoyang Molybdenum (03993), and CICC (03908) experienced the highest net outflows, with amounts of -1.053 billion, -184 million, and -181 million respectively [1] - In terms of net inflow ratios, China Telecom Services (00552), Yihua Tong (02402), and Sunshine Insurance (06963) topped the list with ratios of 167.31%, 126.18%, and 118.17% respectively [1] Net Inflow Rankings - Tencent Holdings (00700) had a net inflow of 1.115 billion, representing a 13.09% increase, closing at 614.500 [2] - Alibaba-W (09988) saw a net inflow of 1.055 billion, with a 12.23% increase, closing at 146.400 [2] - Hong Kong Exchanges (00388) recorded a net inflow of 309 million, with a 24.77% increase, closing at 407.000 [2] Net Outflow Rankings - China Mobile (00941) faced a net outflow of -1.053 billion, a decrease of -54.21%, closing at 83.700 [2] - Luoyang Molybdenum (03993) had a net outflow of -184 million, down by -29.82%, closing at 19.100 [2] - CICC (03908) experienced a net outflow of -181 million, a decrease of -30.22%, closing at 20.540 [2] Net Inflow Ratio Rankings - China Telecom Services (00552) achieved a net inflow ratio of 167.31%, with a net inflow of 26.5926 million, closing at 4.520 [3] - Yihua Tong (02402) had a net inflow ratio of 126.18%, with a net inflow of 26.5481 million, closing at 23.980 [3] - Sunshine Insurance (06963) recorded a net inflow ratio of 118.17%, with a net inflow of 31.5558 million, closing at 3.940 [3]

12月24日上榜的成交活跃股中，石药集团通过港股通渠道成交金额为2.72亿港元，净买入金额为1.00亿 港元，不仅如此，该股已连续3日出现成交净买入，累计净买入金额为2.12亿港元，其间股价上涨 6.95%。（数据宝） （文章来源：证券时报网） 石药集团获南向资金连续3天净买入，累计净买入金额为2.12亿港元，股价累计上涨6.95%。 证券时报·数据宝统计显示，12月24日港股通（包括沪市港股通及深市港股通）成交活跃股合计成交 164.32亿港元，净卖出金额为7.87亿港元。 ...

Core Viewpoint - The Hang Seng Index rose by 0.17% on December 24, with southbound capital recording a total transaction amount of HKD 457.99 billion, resulting in a net sell of HKD 11.75 billion [1] Group 1: Southbound Capital Transactions - Southbound capital transactions included a total of HKD 169.12 billion for the Shenzhen Stock Connect, with a net sell of HKD 6.24 billion, and HKD 288.87 billion for the Shanghai Stock Connect, with a net sell of HKD 5.52 billion [1] - The most active stock for southbound capital was SMIC, with a total transaction amount of HKD 46.18 billion and a net buy of HKD 4.91 billion, closing up by 3.12% [1][2] - Other notable stocks included Alibaba and Tencent, with transaction amounts of HKD 30.19 billion and HKD 16.71 billion, respectively, both experiencing net sells of HKD 2.88 billion and HKD 6.11 billion [1][2] Group 2: Individual Stock Performance - The stocks with the highest net buy amounts included Agricultural Bank with HKD 1.75 billion and Hua Hong Semiconductor with HKD 1.06 billion [1] - China Mobile had the highest net sell amount at HKD 7.11 billion, closing down by 0.06% [1][2] - The stock with the longest consecutive net buy days was CSPC Pharmaceutical, with a total net buy of HKD 2.12 billion over three days [2]

Group 1 - On December 24, 2025, SMIC (00981), Alibaba-W (09988), and China Mobile (00941) were the top three companies by trading volume in the Southbound Stock Connect, with transaction amounts of 2.939 billion, 1.946 billion, and 1.041 billion respectively [1][2] - In the Shenzhen-Hong Kong Stock Connect, SMIC (00981), Alibaba-W (09988), and Tencent Holdings (00700) also ranked as the top three companies by trading volume, with transaction amounts of 1.678 billion, 1.074 billion, and 0.916 billion respectively [1][2] Group 2 - In the Southbound Stock Connect, the top ten active trading companies included SMIC (00981) with a net buying amount of 65.43 million, while Alibaba-W (09988) and China Mobile (00941) had net selling amounts of 1.57 billion and 513 million respectively [2] - In the Shenzhen-Hong Kong Stock Connect, SMIC (00981) had a net buying amount of 425 million, while Alibaba-W (09988) and Tencent Holdings (00700) recorded net selling amounts of 1.31 billion and 553 million respectively [2]

Core Viewpoint - Starting in 2024, the performance of CSPC Pharmaceutical Group has shown a "double decline" in profits and revenues [1][23]. Group 1: Company Developments - CSPC Pharmaceutical Group has been active recently, establishing a joint venture named "CSPC Runshi Biotechnology" with a total investment of 450 million yuan, focusing on the development and commercialization of GLP-1 target-related drugs for diabetes and weight loss [2][17]. - A significant management reshuffle occurred on December 19, with Zhang Cuilong stepping down as CEO and being replaced by Cai Lei, who is the son of the company's chairman and major shareholder, Cai Dongchen [3][9][28]. - Cai Lei's appointment is seen as adding a family business dynamic to the leadership, as he is part of the next generation of the Cai family involved in the company [3][10]. Group 2: Financial Performance - CSPC's revenue for 2024 is reported at 29.009 billion yuan, a decrease of 9.56% year-on-year, while the net profit attributable to shareholders fell by 25.9% to 4.328 billion yuan [13][33]. - The company has continued to experience revenue and profit declines into the first three quarters of 2025, with revenues of 19.891 billion yuan, down 12.32% year-on-year, and a net profit of 3.511 billion yuan, down 7.06% [13][33]. Group 3: Strategic Shifts - The decline in performance is attributed to the impact of national drug procurement policies on the pricing of core products [15][35]. - CSPC is accelerating its transition towards innovative drugs, with nearly 90 products in various stages of clinical trials and a focus on external partnerships to enhance market access and cash flow [15][35]. - The company is also pushing into the GLP-1 market, with at least five related products in the application or licensing stages, indicating a competitive strategy in a growing therapeutic area [17][37]. Group 4: Leadership and Governance - The new leadership structure, characterized by a "brotherly division of labor" model, aims to leverage individual strengths, mitigate operational risks, and ensure a balanced governance structure [5][25]. - Cai Lei's previous experience in the U.S. R&D division is expected to enhance CSPC's international strategy and innovation capabilities [17][37]. - The company has faced scrutiny due to insider trading issues involving former executives, which has influenced recent management changes [10][31].